Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(9):628-630; doi:10.1093/jnci/97.9.628
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

For EGFR Research, New Targeted Drugs Mean New Questions

Brian Vastag

The first 10% of the full text of this article appears below.

In the early 1980s, a pair of researchers at the University of California at San Diego had an idea that was ahead of its time. John Mendelsohn, M.D., and Gordon Sato, M.D., had been studying a cell-surface molecule, the epidermal growth factor receptor (EGFR), that appeared to be a key element in oncogenesis. If they could shut down the receptor, they thought, maybe they could shut down cancer, too. So the team borrowed a motif from the body's immune system and built an antibody—a daunting task then—that clamps onto EGFR. Mouse experiments showed the soundness of their theory: Shutting down the receptor indeed halted the spread of cancer.

Twenty-five years later, the human version of that antibody is now an FDA-approved treatment for lung . . . [Full Text of this Article]

Illuminating Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?